BioAge Labs, Inc. BIOA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -55.63%
- 1 year
- -24.06%
- Open
- 5.86
- Prev close
- 5.94
- Mkt cap
- 269.41M
- Vol
- 801.36K
- Avg vol
- 964.44K
- EPS
- -2.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.63
- High
- 5.93
- Forward P/E
- -12.08
- Beta
- 0.00
- Short ratio
- 4.63
- Inst. own
- 85.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 18.87
- 200-d avg
- 15.13
- 1y target
- 49.50
News
3 days ago zacks.com
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago defenseworld.net
BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison
BioAge Labs (NASDAQ: BIOA - Get Free Report) and Royalty Pharma (NASDAQ: RPRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
2 weeks ago globenewswire.com
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep…
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
1 month ago defenseworld.net
Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA
Bank of America Corp DE acquired a new position in shares of BioAge Labs, Inc. (NASDAQ: BIOA) in the undefined quarter, according to the company in its most recent disclosure with the Securities and…
1 month ago globenewswire.com
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for…
1 month ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago seekingalpha.com
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago seekingalpha.com
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
-
1 month ago benzinga.com
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the…
1 month ago globenewswire.com
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity…
1 month ago seekingalpha.com
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off
BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98%…
2 months ago globenewswire.com
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for…
2 months ago defenseworld.net
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ: BIOA) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange…
2 months ago zacks.com
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.
-
2 months ago benzinga.com
Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60)…
2 months ago globenewswire.com
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026
-
3 months ago benzinga.com
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35
Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
3 months ago benzinga.com
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting…
3 months ago benzinga.com
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
3 months ago benzinga.com
Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings
US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
3 months ago defenseworld.net
BioAge Labs (NASDAQ:BIOA) Trading Up 5.5% – Should You Buy?
BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report)'s stock price rose 5.5% on Friday. The stock traded as high as $23.09 and last traded at $23.3710. Approximately 51,852 shares changed hands during…
-
4 months ago benzinga.com
BioAge Labs Doses First Participant Dosed In QUELL-CV
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular…
4 months ago globenewswire.com
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular…
4 months ago seekingalpha.com
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4 months ago marketbeat.com
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term…
5 months ago benzinga.com
This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.
-
5 months ago benzinga.com
Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36
Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.
5 months ago globenewswire.com
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for…
5 months ago benzinga.com
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday
Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes. See opinions on CSHR, BIOA.
-
5 months ago benzinga.com
BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40
BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $40.
-
5 months ago benzinga.com
Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 44.44 percent decrease over losses of $(0.36)…
6 months ago benzinga.com
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts maintain Buy ratings with higher targets.
6 months ago benzinga.com
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.
7 months ago benzinga.com
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See others' views on these stocks.
-
7 months ago benzinga.com
Needham Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $50
Needham analyst Joseph Stringer initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $50.
-
7 months ago benzinga.com
Bioage Labs Q4 EPS $(0.72) Beats $(0.73) Estimate, Sales $3.078M Beat $1.915M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 22.03 percent decrease over losses of $(0.59)…
-
7 months ago benzinga.com
Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the price target from $15 to $52.
8 months ago benzinga.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
-
8 months ago benzinga.com
Oppenheimer Initiates Coverage On Bioage Labs with Outperform Rating, Announces Price Target of $60
Oppenheimer analyst Jay Olson initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Outperform rating and announces Price Target of $60.
8 months ago benzinga.com
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
-
8 months ago benzinga.com
Jefferies Upgrades Bioage Labs to Buy, Raises Price Target to $62
Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the price target from $9 to $62.
-
9 months ago benzinga.com
Piper Sandler Initiates Coverage On Bioage Labs with Overweight Rating, Announces Price Target of $73
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Overweight rating and announces Price Target of $73.
-
9 months ago benzinga.com
Reported Earlier, BioAge Prices Upsized $115M Public Offering Of 5.9M Shares At $19.50 Per Share
BioAge intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and…
9 months ago benzinga.com
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
9 months ago benzinga.com
BioAge Labs Announces Up To $75M Common Stock Offering
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
9 months ago benzinga.com
BioAge Labs Expands BGE-102 Development Program Into Ophthalmology, With Initial Proof-Of-Concept Study In Patients With Diabetic Macular Edema
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapiesGrowing preclinical and…